Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Dec 06, 2024

BUY
$3.01 - $7.45 $33,007 - $81,696
10,966 New
10,966 $57,000
Q1 2024

May 15, 2024

SELL
$3.01 - $7.45 $15,757 - $39,000
-5,235 Reduced 32.31%
10,966 $57,000
Q4 2023

Feb 14, 2024

BUY
$1.4 - $3.24 $22,681 - $52,491
16,201 New
16,201 $49,000
Q2 2023

Aug 14, 2023

SELL
$4.3 - $9.48 $1.5 Million - $3.3 Million
-347,897 Reduced 96.24%
13,575 $93,000
Q1 2023

May 15, 2023

BUY
$4.81 - $8.88 $265,569 - $490,282
55,212 Added 18.03%
361,472 $2.24 Million
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $34,751 - $42,906
5,330 Added 1.77%
306,260 $2.19 Million
Q3 2022

Mar 03, 2023

SELL
$7.57 - $12.5 $40,348 - $66,625
-5,330 Reduced 1.74%
300,930 $2.33 Million
Q3 2022

Nov 14, 2022

BUY
$7.57 - $12.5 $2.18 Million - $3.6 Million
287,704 Added 2175.29%
300,930 $2.33 Million
Q1 2022

May 16, 2022

SELL
$7.09 - $89.45 $112,014 - $1.41 Million
-15,799 Reduced 54.43%
13,226 $102,000
Q4 2021

Feb 14, 2022

SELL
$80.85 - $128.49 $2.35 Million - $3.73 Million
-29,067 Reduced 50.04%
29,025 $2.46 Million
Q3 2021

Nov 15, 2021

SELL
$81.97 - $106.94 $347,716 - $453,639
-4,242 Reduced 6.81%
58,092 $5.58 Million
Q2 2021

Aug 16, 2021

BUY
$77.2 - $126.54 $3.7 Million - $6.07 Million
47,953 Added 333.45%
62,334 $5.8 Million
Q1 2021

May 17, 2021

BUY
$110.45 - $164.47 $37,773 - $56,248
342 Added 2.44%
14,381 $1.63 Million
Q4 2020

Feb 16, 2021

BUY
$60.78 - $154.03 $243,788 - $617,814
4,011 Added 40.0%
14,039 $2.06 Million
Q2 2020

Aug 14, 2020

SELL
$42.74 - $66.25 $165,361 - $256,321
-3,869 Reduced 27.84%
10,028 $543,000
Q1 2020

May 15, 2020

BUY
$38.18 - $73.95 $85,561 - $165,721
2,241 Added 19.23%
13,897 $663,000
Q4 2019

Feb 14, 2020

BUY
$13.9 - $76.65 $162,018 - $893,432
11,656 New
11,656 $839,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $455M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.